Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 261

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Mayer, Erica L, Dueck, Amylou C, Martin, Miguel, Rubovszky, Gabor, Burstein, Harold J, Bellet-Ezquerra, Meritxell, Miller, Kathy D, Zdenkowski, Nicholas, Winer, Eric P, Pfeiler, Georg, Goetz, Matthew, Ruiz-Borrego, Manuel, Anderson, Daniel, Nowecki, Zbigniew, Loibl, Sibylle, Moulder, Stacy, Ring, Alistair, Fitzal, Florian, Traina, Tiffany, Chan, Arlene, Rugo, Hope S, Lemieux, Julie, Henao, Fernando, Lyss, Alan, Antolin Novoa, Silvia, Wolff, Antonio C, Vetter, Marcus, Egle, Daniel, Morris, Patrick G, Mamounas, Eleftherios P, Gil-Gil, Miguel J, Prat, Aleix, Fohler, Hannes, Metzger Filho, Otto, Schwarz, Magdalena, DuFrane, Carter, Fumagalli, Debora, Theall, Kathy Puyana, Lu, Dongrui Ray, Bartlett, Cynthia Huang, Koehler, Maria, Fesl, Christian, DeMichele, Angela, Gnant, Michael·2021·The Lancet Oncology

Abstract

BACKGROUND Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib to adjuvant endocrine therapy improves invasive disease-free survival over endocrine therapy alone in patients with hormone-receptor-positive, HER2-negative, early-stage breast cancer. METHODS PALLAS is an ongoing multicentre, open-label, randomised, phase 3 study that enrolled patients at 406 cancer centres in 21 countries worldwide with stage II-III histologically confirmed hormone-receptor-positive, HER2-negative breast cancer, within 12 months of initial diagnosis. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance score of 0 or 1. Patients were randomly assigned (1:1) in permuted blocks of random size (4 or 6), stratified by anatomic stage, previous chemotherapy, age, and geographical region, by use of central telephone-based and web-based interactive response technology, to receive either 2 years of palbociclib (125 mg orally once daily on days 1-21 of a 28-day cycle) with ongoing standard provider or patient-choice adjuvant endocrine therapy (tamoxifen or aromatase inhibitor, with or without concurrent luteinising hormone-releasing hormone agonist), or endocrine therapy alone, without masking. The primary endpoint of the study was invasive disease-free survival in the intention-to-treat population. Safety was assessed in all randomly assigned patients who started palbociclib or endocrine therapy. This report presents results from the second pre-planned interim analysis triggered on Jan 9, 2020, when 67% of the total number of expected invasive disease-free survival events had been observed. The trial is registered with ClinicalTrials.gov (NCT02513394) and EudraCT (2014-005181-30). FINDINGS Between Sept 1, 2015, and Nov 30, 2018, 5760 patients were randomly assigned to receive palbociclib plus endocrine therapy (n=2883) or endocrine therapy alone (n=2877). At the time of the planned second interim analysis, at a median follow-up of 23·7 months (IQR 16·9-29·2), 170 of 2883 patients assigned to palbociclib plus endocrine therapy and 181 of 2877 assigned to endocrine therapy alone had invasive disease-free survival events. 3-year invasive disease-free survival was 88·2% (95% CI 85·2-90·6) for palbociclib plus endocrine therapy and 88·5% (85·8-90·7) for endocrine therapy alone (hazard ratio 0·93 [95% CI 0·76-1·15]; log-rank p=0·51). As the test statistic comparing invasive disease-free survival between groups crossed the prespecified futility boundary, the independent data monitoring committee recommended discontinuation of palbociclib in patients still receiving palbociclib and endocrine therapy. The most common grade 3-4 adverse events were neutropenia (1742 [61·3%] of 2840 patients on palbociclib and endocrine therapy vs 11 [0·3%] of 2903 on endocrine therapy alone), leucopenia (857 [30·2%] vs three [0·1%]), and fatigue (60 [2·1%] vs ten [0·3%]). Serious adverse events occurred in 351 (12·4%) of 2840 patients on palbociclib plus endocrine therapy versus 220 (7·6%) of 2903 patients on endocrine therapy alone. There were no treatment-related deaths. INTERPRETATION At the planned second interim analysis, addition of 2 years of adjuvant palbociclib to adjuvant endocrine therapy did not improve invasive disease-free survival compared with adjuvant endocrine therapy alone. On the basis of these findings, this regimen cannot be recommended in the adjuvant setting. Long-term follow-up of the PALLAS population and correlative studies are ongoing. FUNDING Pfizer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30642-2

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 261

Metadata

Authors
Mayer, E. L., Dueck, A. C., Martin, M., Rubovszky, G., Burstein, H. J., Bellet-Ezquerra, M., Miller, K. D., Zdenkowski, N., Winer, E. P., Pfeiler, G., Goetz, M., Ruiz-Borrego, M., Anderson, D., Nowecki, Z., Loibl, S., Moulder, S., Ring, A., Fitzal, F., Traina, T., Chan, A., Rugo, H. S., Lemieux, J., Henao, F., Lyss, A., Antolin Novoa, S., Wolff, A. C., Vetter, M., Egle, D., Morris, P. G., Mamounas, E. P., Gil-Gil, M. J., Prat, A., Fohler, H., Metzger Filho, O., Schwarz, M., DuFrane, C., Fumagalli, D., Theall, K. P., Lu, D. R., Bartlett, C. H., Koehler, M., Fesl, C., DeMichele, A., & Gnant, M.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-02
Volume
22
Issue
2
Pages
212-222
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3120241209
Cited by
261
References
35
FWCI
29.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30642-2
The paper
Mayer, E. L., Dueck, A. C., Martin, M., Rubovszky, G., Burstein, H. J., Bellet-Ezquerra, M., Miller, K. D., Zdenkowski, N., Winer, E. P., Pfeiler, G., Goetz, M., Ruiz-Borrego, M., Anderson, D., Nowecki, Z., Loibl, S., Moulder, S., Ring, A., Fitzal, F., Traina, T., . . . Gnant, M. (2021). Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30642-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.